Evidence map›Paper›PMID 40385366›Full record

ArticleNuclear medicine and molecular imaging2025

Quantification of

Makoto Ohba, Takeo Tanada, Yasushi Ishikawa, Satomi Teraoka, Kazukuni Kirii, Shin Ohara, Ayato Taketa, Taiyo Tanae, Yosuke Moriya, Koji Suzuki and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Makoto OhbaDepartment of Radiology, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585 Japan.ORCID 0000-0002-3561-9175
Takeo TanadaDepartment of Radiology, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585 Japan.
Yasushi IshikawaPDRadiopharma Inc., Tokyo, Japan.
Satomi TeraokaPDRadiopharma Inc., Tokyo, Japan.
Kazukuni KiriiDivision of Diagnostic Radiology, Department of Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Shin OharaDivision of Diagnostic Radiology, Department of Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Ayato TaketaDivision of Diagnostic Radiology, Department of Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Taiyo TanaeDivision of Diagnostic Radiology, Department of Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Yosuke MoriyaDivision of Diagnostic Radiology, Department of Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Koji SuzukiDepartment of Radiology, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585 Japan.
Masafumi KanotoDivision of Diagnostic Radiology, Department of Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Neuroendocrine tumors (NETs) can be classified into three grades based on the malignancy index identified via histological and pathological diagnosis, and Methods: Twenty-two patients underwent Results: The ⊿tumor SUV Conclusion: The ⊿tumor SUV (24 h-4 h) in patients with pancreatic/gastrointestinal NET on

Indexed as

111In-pentetreotideNeuroendocrine tumorSingle photon emission computed tomographySomatostatin receptorStandardized uptake value

Identifiers

PMID40385366
PMCPMC12084186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.